The multiple myeloma treatment landscape plays a significant role in supporting improved patient outcomes by providing an evolving mix of proteasome inhibitors, immunomodulatory agents, monoclonal antibodies, and cell-based therapies. Pharmaceutical developers are increasingly incorporating targeted mechanisms and immunotherapy platforms that improve response rates and long-term survival. The...